Related by context. All words. (Click for frequent words.) 70 DAS# scores 70 Complication rates 70 nondiabetic patients 69 PASI scores 68 laboratory abnormalities 68 HbA1C levels 68 NHANES III 67 baseline HbA1c 67 preintervention 67 baseline A1C 66 TEAEs 66 nonobese 66 nondiabetic 65 MMSE scores 65 HbA 1c levels 65 postintervention 65 odds ratios ORs 65 prospectively stratified 65 definite stent thrombosis 65 Hb A1C 65 MMSE score 65 fasting triglyceride levels 65 tumor histology 65 oxycodone CR 65 comparator arm 64 mcg albinterferon alfa 2b 64 MADRS score 64 tertile 64 Median survival 64 telomere lengths 64 CR nPR 64 CHD mortality 64 virologic responses 64 HIV HCV coinfected 64 Secondary efficacy endpoints 64 PREZISTA r arm 64 histologies 64 elevated LDH 64 allele frequencies 64 transaminase elevations 64 advanced adenomas 64 relapsed MM 63 ALT flares 63 tertiles 63 Index CDAI 63 HbA 1c 63 hsCRP levels 63 hemoglobin A1c levels 63 dapagliflozin plus 63 antiretroviral naïve 63 HbA1c levels 63 #mg BID [001] 63 endometrial thickness 63 Pharmacokinetic parameters 63 mcg QD 63 psychiatric comorbidities 63 seroprotection 63 HBeAg negative patients 63 posttreatment 63 System IPSS 63 highest tertile 63 Subgroup analyzes 63 nondepressed 63 oncologic outcomes 63 nulliparous women 63 prospectively defined 63 sociodemographic variables 63 % CI #.#-#.# [003] 63 multivariate analyzes 63 thyrotropin levels 63 poor metabolizers 63 serum lipid levels 63 hip BMD 63 REYATAZ r arm 63 EDSS scores 63 NNT = 63 QTcF 63 HER2 expression 63 intima media thickness 63 β blockers 63 Adverse events 63 umol L 62 stage IIIb IV 62 -#.# log# 62 metabolic parameters 62 diastolic blood pressures 62 lopinavir r arm 62 CCyR 62 lipid lowering agents 62 HIV uninfected 62 mcg BID 62 NATRECOR R 62 timepoints 62 neutrophil counts 62 Platelet counts 62 coinfected 62 confidence interval CI 62 attain statistical significance 62 fasting insulin 62 interquartile range 62 underwent CABG 62 ± SD 62 femoral neck BMD 62 certolizumab 62 lymphocytosis 62 recurrent VTE 62 HAQ DI 62 tipranavir ritonavir 62 virologic response 62 confidence intervals CIs 62 glycated hemoglobin levels 62 Operative mortality 62 metformin monotherapy 62 EDSS score 62 -#.# log# copies mL 62 logistic regression models 62 advanced adenoma 62 underwent resection 62 estimated glomerular filtration 62 CVD mortality 62 LVEF 62 carotid IMT 62 HBeAg negative 62 CPAP adherence 62 oral hypoglycemic agent 62 venlafaxine XR 62 serum concentrations 62 systolic dysfunction 62 PREZISTA r 62 ejection fractions 62 TT genotype 61 histologic subtype 61 #mg/day [001] 61 microbiologically evaluable 61 normotensive 61 serum creatinine levels 61 CYPHER Stent 61 #mg BID [003] 61 oxycodone IR 61 affective psychosis 61 glycosylated hemoglobin levels 61 haematologic 61 #mg BID [002] 61 pCR 61 FOLPI 61 Secondary endpoints 61 MetS 61 nonfatal MI 61 coinfected patients 61 methotrexate monotherapy 61 placebo fluoxetine 61 echocardiographic parameters 61 coronary calcification 61 monozygotic twin 61 LEXIVA r 61 VLBW 61 trials RCTs 61 hemoglobin concentrations 61 #q# deletion syndrome 61 elevated ALT 61 Descriptive statistics 61 lowest tertile 61 lopinavir r 61 metabolite concentrations 61 endoscopic remission 61 covariate 61 ANCOVA 61 arterial thickening 61 Triglyceride levels 61 nonexposed 61 SGRQ 61 radical nephrectomy 61 androgen excess 61 lumbar spine BMD 61 aged ≥ 61 dyslipidaemia 61 HBeAg seroconversion 61 biochemical recurrence 61 APTIVUS r 61 colorectal polyp 61 mg kg dose 61 IFN alfa 61 MacroChem actual 61 mL/min/#.# m 2 61 daunorubicin 61 placebo dexamethasone 61 angiographic outcomes 61 pulmonary dysfunction 61 undetectable HBV DNA 61 neurologic outcomes 61 bezafibrate 61 nonfasting triglyceride levels 61 glycosylated hemoglobin HbA1c 61 antibody titer 61 colorectal adenoma 61 achieved ACR# 61 flutamide 61 multivariable analysis 61 PSA nadir 61 active comparator 60 oral olanzapine 60 perinatal outcomes 60 NIHSS 60 BMI z 60 recurrent venous thromboembolism 60 morphometric vertebral fractures 60 hematologic toxicity 60 prognostic factors 60 infliximab monotherapy 60 HRQL 60 KRAS mutations occur 60 NPH insulin 60 intact parathyroid hormone 60 evaluable subjects 60 ALT elevation 60 achieved statistical significance 60 ipsilateral stroke 60 hepatorenal syndrome 60 antiretroviral naive 60 clinically meaningful differences 60 perioperative complications 60 prevalences 60 CORE OM 60 serum PTH 60 galiximab 60 receiving ISENTRESS 60 #.#mg/dL 60 % CI #.#-#.# [007] 60 fasting glucose levels 60 locoregional recurrence 60 adiponectin concentrations 60 sociodemographic factors 60 underwent surgical resection 60 aldosterone antagonist 60 baseline CD4 60 CARDIA 60 sleeve lobectomy 60 hippocampal volumes 60 Symptom severity 60 Flu Cy 60 insulin detemir 60 squamous histology 60 symptomatic intracerebral hemorrhage 60 Meta analyzes 60 liver transplant recipients 60 nonmetastatic 60 multiple logistic regression 60 Primary endpoints 60 ECOG PS 60 chronic periodontitis 60 chlorthalidone 60 corrected QT interval 60 virologic failure 60 parous 60 mean ± SEM 60 serum calcium levels 60 autonomic dysfunction 60 sd = 60 PREZISTA rtv 60 comorbid illnesses 60 monozygotic 60 sociodemographic 60 μmol L 60 colorectal neoplasia 60 hematological parameters 60 nonrandomized 60 infarcts 60 glycated hemoglobin HbA1c 60 lymphadenectomy 60 BMD measurements 60 serum IGF 60 p = .# [002] 60 treated nonoperatively 60 serum phosphate levels 60 lipid lowering medications 60 sociodemographic characteristics 60 Folfox 60 P = .# 60 #mmHg [001] 60 receiving TNF blockers 60 baseline LDH 60 nonpregnant women 60 fasting plasma glucose FPG 60 dizygotic 60 advanced neoplasia 60 diastolic pressures 60 Hb A1c 60 aminotransferase levels 60 serum calcium 60 CC genotype 60 dizygotic twins 60 genotypic resistance 60 MELD scores 60 plasma folate 60 histological subtypes 60 comorbid conditions 60 Swedish Mammography Cohort 60 FluCAM 60 IBDQ 60 CrCl 60 postoperative chemotherapy 60 PCWP 60 malignant polyps 60 pharmacokinetic characteristics 60 Charlson comorbidity index 60 multivariable adjusted 60 prospective observational studies 60 HBeAg positive 60 baseline FEV 60 perioperative mortality 60 dacarbazine chemotherapy 60 binary restenosis 60 pharmacodynamic parameters 60 pegylated interferon alfa 2b 60 retrospective cohort 60 CLA supplementation 60 male Wistar rats 60 dose regimens 60 seronegative 60 hepatitis C genotype 60 Crohn Disease Activity 59 p = NS 59 progression TTP 59 moderate renal impairment 59 discontinuations due 59 specific antigen PSA 59 events SAEs 59 % Confidence Interval 59 μg L 59 apolipoprotein B 59 CANCIDAS 59 % CI #.#-#.# [008] 59 nonoperative 59 oral antidiabetic agents 59 nonadherent 59 N telopeptide 59 rCBF 59 tapentadol ER 59 HIV seronegative 59 Multivariate analyzes 59 ng dL 59 #.#ng/ml 59 Insulin sensitivity 59 sUA 59 GH deficiency 59 statistical significance p 59 bivariate analyzes 59 abacavir lamivudine 59 serum clusterin levels 59 intraobserver 59 univariate 59 undergone radical prostatectomy 59 LV dysfunction 59 avosentan 59 NNRTI resistance 59 Non inferiority 59 secondary efficacy endpoints 59 arterial thromboembolic events 59 heavily pretreated 59 intracranial hemorrhage ICH 59 NYHA functional class 59 prednisone prednisolone plus 59 serum leptin 59 nadroparin 59 ELBW infants 59 univariate analyzes 59 postoperative mortality 59 hormone receptor negative 59 CI -#.# 59 nonischemic 59 nonvertebral fracture 59 hematopoietic cancers 59 #mg dose [002] 59 4mg/kg 59 CLBP 59 lipid concentrations 59 HOMA IR 59 dosage regimens 59 plus methotrexate 59 DAS# remission 59 mmol l 59 hemodynamically significant 59 BRCA1 mutation carriers 59 immunocompetent 59 % CI #.#-#.# [006] 59 Exclusion criteria 59 subclinical hypothyroidism 59 pathologic fractures 59 retinal thickness 59 cTnT levels 59 MACCE 59 prespecified 59 pulsatile flow 59 verum acupuncture 59 decompensated liver disease 59 multivariate logistic regression 59 lamivudine monotherapy 59 FDG PET scans 59 intraocular inflammation 59 clinically evaluable 59 generalized edema 59 limiting generalizability 59 preoperative PSA 59 systolic blood pressures 59 PREZISTA ritonavir 59 histologically confirmed 59 bortezomib refractory 59 Wisconsin Sleep Cohort 59 pg ml 59 osteopenic 59 statistically significant differences 59 hormone receptor status 59 baseline serum creatinine 59 SUVmax 59 chlorambucil 59 osteosarcomas 59 mg BID 59 MADIT CRT trial 59 serum urate 59 noninfected 59 symptomatic VTE 59 noncardiovascular mortality 59 spontaneous bowel movements 59 NRTI sparing 59 ACR# responses 59 preoperatively 59 oral diclofenac 59 oral antidiabetic medication 59 renal cell carcinomas 59 adjunctive placebo 59 titrated glipizide 59 paricalcitol 59 seminomas 59 confidence interval #.#-#.# 59 VTEs 59 pyelonephritis 59 statin monotherapy 59 SCr 59 CI #.#-#.# [001] 59 adverse reactions incidence 59 polytherapy 59 multivessel disease 59 hemoglobin A1c HbA1c 59 statistically significant correlations 59 low dose cytarabine 59 onset diabetes mellitus 59 euthymic 59 systemic embolism 59 PLX STROKE targeting 59 diastolic BP 58 A1c levels 58 anemia neutropenia 58 prostate cancer CaP 58 dose cytarabine 58 events AEs 58 Osteoporotic Fractures 58 mean baseline A1C 58 pulmonary artery banding 58 PCA3 scores 58 deep venous thromboses 58 neurodevelopmental outcome 58 timepoint 58 experienced virologic failure 58 Fasting blood glucose 58 nonvertebral fractures 58 ductal breast cancer 58 BENICAR HCT 58 clinicopathologic 58 DAS# CRP 58 adjunctive ABILIFY 58 hypoglycemic events 58 multivariable Cox 58 alanine aminotransferase ALT 58 tapentadol IR 58 hip resurfacing arthroplasty 58 VADT 58 nicardipine 58 desvenlafaxine succinate 58 lactate dehydrogenase 58 statistically nonsignificant 58 LAB GHRH 58 observational cohort 58 severe renal impairment 58 seropositivity 58 GnRH agonist 58 logistic regression model 58 oral antidiabetes drugs 58 neurodevelopmental impairment 58 irbesartan 58 pyridostigmine 58 mg RDEA# 58 subthreshold depression 58 neurologic abnormalities 58 CIMZIA TM 58 conditional logistic regression 58 Univariate analysis 58 underwent radical prostatectomy 58 de novo AML 58 liver histology 58 subtrochanteric 58 Rectal cancer 58 atherogenic dyslipidemia 58 log# copies mL 58 hydroxyvitamin D concentrations 58 subgroup analyzes 58 abnormal glucose tolerance 58 nmol l 58 HIV RNA 58 logistic regression analysis 58 Breslow thickness 58 KRAS mutations 58 urolithiasis 58 paclitaxel eluting stents 58 DAS# [002] 58 HbA 1C 58 leucopenia 58 mg ustekinumab 58 clinico pathological 58 antihypertensive medications 58 TAVR 58 euthyroid 58 oral Hycamtin 58 carotid stenosis 58 extrapyramidal symptoms 58 dysglycemia 58 Cortisol levels 58 hypogonadal 58 postoperative AF 58 tipranavir r 58 concomitant medications 58 mg BID dose 58 serum phosphate 58 abdominal circumference 58 prespecified secondary 58 HRQoL 58 lifetime abstainers 58 typical antipsychotics 58 mRS 58 inhaled glucocorticoids 58 prognostic variables 58 CIN3 58 CIMZIA TM certolizumab pegol 58 receiving antiretroviral therapy 58 fluoxetine paroxetine 58 BRCA2 mutation carriers 58 abnormal lipid 58 Munghana Lonene Listenership 58 parkinsonian symptoms 58 Psoriasis Area 58 mg/m2 dose 58 Lumbar spine 58 ovarian carcinoma 58 hepatic resection 58 nmol liter 58 SHBG levels 58 androgen suppression 58 medically inoperable 58 univariate analysis 58 exploratory endpoints 58 UPDRS motor 58 PLCO 58 plasma creatinine 58 periprocedural 58 Stent thrombosis 58 leukocyte count 58 8mg/kg 58 glomerular filtration 58 elevated hsCRP 58 histologically 58 T2 lesions 58 LDL particle 58 quetiapine risperidone 58 nonfasting 58 mg FV 58 tirofiban 58 K ras mutations 58 serum vitamin D 58 covariates 58 oral hypoglycemic agents 58 events TEAEs 58 treatment emergent adverse 58 glomerular filtration rate 58 coronary stenosis 58 nodular partial response 58 urine albumin 58 XELOX 58 potential confounders 58 thoracoscopic lobectomy 58 depressive symptomatology 58 Adverse effects 58 hydroxyvitamin D levels 58 vertebral fracture 58 symptom exacerbation 58 mIU L 58 follicular lymphoma FL 58 glycated hemoglobin 58 neurocognitive function 58 pT3 58 tolterodine ER 58 Unified Parkinson Disease 58 nulliparous 58 RLAI 58 FluCAM arm 58 dose statin therapy 58 placebo controlled clinical trials 58 atypical hyperplasia 58 Serious adverse reactions 58 subclinical hyperthyroidism 58 antiangiogenic therapy 58 HRQOL 58 concomitant AEDs 58 aminotransferases 58 meta regression 58 ACTEMRA TM 58 anthropometric measures 58 Poisson regression 58 HER2 positive cancers 58 waist girth 58 euthymic patients 58 graft occlusion 58 mm Hg diastolic 58 tamoxifen Nolvadex ® 58 TMC# r 58 contralateral breast cancer 58 axillary lymph nodes 58 neurologic complications 58 ß blockers 58 albumin excretion 58 psychiatric comorbidity 58 UPDRS scores 58 Taxus Stent 58 resected pancreatic cancer 58 salpingo oophorectomy 58 non squamous histology 58 postmenopausal osteoporotic women 58 carotid artery thickness 58 kg m² 58 androgen depletion 58 ng dl 58 unstable angina pectoris 58 T1DM 58 Fibromyalgia Impact Questionnaire 58 underwent liver transplantation 58 demographic subgroups 58 troponin T 58 COPD exacerbation 58 isolated systolic hypertension 57 Fasting glucose 57 inhaled budesonide 57 inflammatory biomarkers 57 LPV r 57 hours postdose 57 BMI ≥ 57 rimonabant #mg 57 amoxicillin clavulanate 57 carotid plaque 57 nonpsychotic 57 APOE genotype 57 transaminase levels 57 mg TID 57 Kaplan Meier analysis 57 PSADT 57 non adjuvanted vaccines 57 Scale EDSS 57 extracapsular extension 57 Immune responses 57 dalteparin 57 comorbidities 57 Engerix B 57 serum estradiol 57 eGFR 57 basal cell nevus syndrome 57 creatinine ratio 57 thromboembolic complications 57 dose proportionality 57 plus OBT 57 creatinine clearance 57 stepwise logistic regression 57 pancreatic adenocarcinoma 57 VO2 peak 57 elevated LDL cholesterol 57 CIMZIA ™ 57 LS BMD 57 TDF FTC 57 serum uric acid 57 ARB telmisartan 57 CHD CVD 57 pg mL 57 vaginal progesterone gel 57 lipid lowering therapy 57 p = #.# [003] 57 Lucentis monotherapy 57 nonsignificant difference 57 EpCAM expression 57 μg dose 57 WOMAC scores 57 retransplantation 57 serum HBV DNA 57 everolimus eluting stents 57 INVEGA ® 57 mg/m2 cohort 57 MDRD 57 lipid parameters 57 mild renal insufficiency 57 coronary stenoses 57 BMI waist circumference 57 follicular lymphomas 57 pooled comparator 57 per deciliter mg 57 Febrile neutropenia 57 n = 57 neurocognitive functioning 57 RECIST Response Evaluation Criteria 57 statistically significant p = 57 severe periodontitis 57 p = .# [001] 57 oral allopurinol 57 NYHA class 57 mcg Albuferon 57 atazanavir ritonavir 57 thromboprophylaxis 57 AGILECT R 57 radiochemotherapy 57 GnRH agonists 57 methotrexate therapy 57 serum phosphorous 57 nondemented 57 mineral density 57 estimated GFR 57 median CD4 57 Herpes infections 57 multivariable analyzes 57 evaluable 57 serum urate levels 57 normal birthweight 57 HCV genotype 57 serum GGT 57 QT intervals 57 cerebral oxygenation 57 preoperative chemotherapy 57 solifenacin 57 2D 4D ratio 57 vesicoureteral reflux 57 seroconverted 57 % CI #.#-#.# [005] 57 median survivals 57 metastatic HRPC 57 quartiles 57 conventional DMARDs 57 gestational hypertension 57 Univariate 57 leukopenia 57 IV bisphosphonates 57 FOSRENOL ® 57 thyroid hormone levels 57 serum ALT 57 prepregnancy BMI 57 perioperatively 57 Apgar scores 57 chorioamnionitis 57 Homocysteine levels 57 liver biopsies 57 randomized #:#:# 57 stage IIIB 57 hallux valgus 57 macrovascular disease 57 severe mitral regurgitation 57 ocular adverse 57 fosamprenavir 57 ADAS cog 57 multivariate Cox 57 NSTE ACS 57 renal cortical 57 bivariate 57 anemia hemoglobin 57 Bonferroni correction 57 endocasts 57 KRAS status 57 intravenous bisphosphonates 57 Score TOS 57 interferon alfa 2b 57 hemorrhagic complications 57 adenotonsillectomy 57 colorectal carcinomas 57 serum testosterone 57 % CI #.#-#.# [004] 57 4CMenB 57 postdischarge 57 histologic subtypes 57 glimepiride 57 CYPHER R stent 57 hepatectomy 57 gp# vaccine 57 elevated serum creatinine 57 unformulated vaccine 57 mg Pycnogenol 57 leptin concentrations 57 nodal metastases 57 DLQI 57 Avandia Actos 57 hyperphenylalaninemia HPA due 57 mean baseline HbA1c 57 IOP lowering 57 cytogenetic responses 57 monozygotic twins 57 headache nasopharyngitis 57 bilateral TKA 57 diuretic chlorthalidone 57 doxorubicin cyclophosphamide 57 glipizide plus 57 psychiatric morbidity 57 -#.# ± [002] 57 hyperbilirubinemia 57 completely resected 57 NNRTI resistant virus 57 #.#/#.# mmHg [001] 57 revascularization procedures 57 pramlintide metreleptin combination 57 plasma leptin 57 placebo controlled trials 57 postmenopausal hormones 57 β blocker 57 lipid profiles 57 linaclotide treated 57 postoperative complication 57 QRS duration 57 myocardial infarctions 57 Free Survival PFS 57 hepatocellular carcinomas 57 aspirin clopidogrel 57 logistic regression analyzes 57 histological subtype 57 FDA defined valvulopathy 57 Serious AEs 57 TAXUS Stent 57 highest quintile 57 varicoceles 57 CNS systemic embolism 57 dizziness nausea diarrhea 57 primary hypercholesterolemia 57 white matter hyperintensities 57 prolactin elevation 57 receiving VICTRELIS 57 receiving XGEVA 57 mg QD 57 pyrexia mucositis sepsis febrile 57 Postoperatively 57 mcg doses 57 undergoing bariatric surgery 57 multicenter multinational 57 Viread Emtriva Sustiva 57 Montgomery Asberg Depression 57 5-FU/LV 57 urate levels 57 5mg dose 57 gastric cardia 57 vWD 57 severe exacerbations 57 cytogenetic response 57 placebo controlled dose escalation 57 prospectively randomized 57 #mg doses [002] 57 postoperative morbidity 56 urinary N telopeptide 56 INTERHEART study 56 Logistic regression 56 sonographic findings 56 T1c 56 mutated K ras 56 hyper IgE syndrome 56 asymptomatic PAD 56 internalizing disorders 56 d dimer 56 shorter telomere length 56 posaconazole 56 -#.# mg dL [002] 56 otamixaban 56 triglyceride concentration 56 kidney allograft 56 peak VO2 56 chlamydial infection 56 psychiatric outpatients 56 CK # plasma concentrations 56 parous women 56 baseline PASI 56 del 5q MDS 56 pegylated liposomal doxorubicin 56 mEq L 56 dietary calcium intake 56 elevated IOP 56 cerebrovascular events 56 symptomatic BPH 56 antidiabetic therapy 56 riociguat 56 nocturnal hypoglycaemia 56 #mg/day [002] 56 hemodynamic parameters 56 alanine aminotransferase 56 splenectomized patients 56 revascularizations 56 micafungin 56 ischemic cardiomyopathy 56 receiving Vectibix monotherapy 56 overt nephropathy 56 osteopathic manipulation 56 sotalol 56 macrovascular events 56 NIHSS score 56 atherosclerotic renal artery stenosis 56 normoxic 56 sustained virological response 56 serum phosphorus 56 triglyceride concentrations 56 placebo dummy pill 56 PASI score 56 syndromal 56 Radical prostatectomy 56 ICDs implanted 56 SCIg 56 stone formers 56 baseline Hb 56 nondiabetic subjects 56 Erectile function 56 undergone hysterectomies 56 comorbid disorders 56 triacylglycerol concentrations 56 secondary efficacy endpoint 56 ALI ARDS 56 g dL 56 PsA 56 lobular carcinomas 56 elevated fasting glucose 56 potent antiretroviral therapy 56 lymph node involvement 56 ALLHAT 56 unfractionated heparin UFH 56 efficacy evaluable 56 macroalbuminuria 56 Framingham Offspring Study 56 peginterferon alfa 2b 56 p# biomarker 56 VaD 56 heavily pretreated patients 56 radical prostatectomy RP 56 polyp recurrence 56 familial clustering 56 Multivariate analysis 56 hypertension hypercholesterolemia 56 SSRI SNRI 56 hematologic parameters 56 aspartate aminotransferase AST 56 operable breast cancer 56 serum lipid 56 mU L 56 myocardial infarctions MIs 56 schizophreniform disorder 56 plain radiographs 56 URTI 56 unfractionated heparin 56 mITT 56 mg eq 56 pravastatin therapy 56 undergoing CABG 56 rizatriptan 56 leukemia multiple myeloma 56 ADCS CGIC 56 LDL cholesterol concentrations 56 cisplatin vinorelbine 56 visceral metastases 56 symptomatic hyponatremia 56 prospective observational cohort 56 suicide attempters 56 Kaplan Meier survival 56 radiographic findings 56 virologically 56 complete cytogenetic response 56 #mg/dL [001] 56 #mg ATC 56 Renal Cell Carcinoma RCC 56 mucinous 56 clinically localized prostate 56 kg/m2 56 dosing cohort 56 risperidone olanzapine 56 vitreous floaters 56 confounding variables 56 Multicenter AIDS 56 intensive lipid lowering 56 nonsignificant 56 Scale EDSS score 56 HAART regimens 56 antiandrogen 56 Kaplan Meier curves 56 overt hypothyroidism 56 ± SEM 56 μg doses 56 glycoprotein IIb IIIa inhibitors 56 dose cohorts 56 telaprevir dosing